Biotech entity
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention Andrew Robbins, the most common co-covered peer. The tracked stories average 2 original sources each. CGT1145 appears in 1 tracked Biotech story from July 12, 2026.
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention Andrew Robbins, the most common co-covered peer. The tracked stories average 2 original sources each. CGT1145 appears in 1 tracked Biotech story from July 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CGT1145. Shared-story counts are live from our verified record — not editorial picks.
The biotech’s novel inhibitor could redefine the JAK2-targeted therapy landscape, with preclinical data supporting disease-modifying potential ahead of a planned IND submission this year. Investors watch for Phase 1 timing.
Source: insidermonkey.com · finance.yahoo.com
CGT1145 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
